Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in terms of ‘beyond-the-pill’ approaches, the unique commitment of the company to significantly raise patient outcomes in Mexico, becoming the partner of choice of Mexican public partners, and further expanding strategic investments in the country.
When you became president of CANIFARMA in March 2015, one of the Chamber’s first and foremost priorities was to ensure the pharmaceutical industry would be officially recognized as a strategic sector for Mexico’s economy. From your dialogue with Mexico’s Secretaries of Economy and Health, why are you confident the country’s pharmaceutical industry will soon be able to reach this important recognition?
Pharmaceutical investments in Mexico are growing faster than our production volume, while clinical trial activities, which represent high-added value investments, are the fastest growing investment segment of our industry
